قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Dow Jones Futures: Zogenix Dives; GW Pharma, PhaseBio Pop on FDA News

Dow Jones Futures: Zogenix Dives; GW Pharma, PhaseBio Pop on FDA News



The Dow Jones sweatshirts fell at the end of Monday, as well as the S & P 500 Sweepstakes and Nasdaq Sweatshirts. After closing the FDA, rejected the drug Zogenix (ZGNX) for the rare form of epilepsy, a good news for GW Pharma (GWPH). Meanwhile, the FDA granted the PhaseBio Pharmaceuticals (PHAS) Phase Therapy Breakthrough status. In addition, the FDA also entered the system of blood typing and screening Bio-Rad Laboratories (BIO). Stock Zogenix declined after hours, while GW Pharma shares and PhaseBio shares gathered.




X



Dow Jones Today

Dow Jones sweatshirts declined by 0.2% compared to fair value. S & P 500 yarns dropped by 0.2%. The Nasdaq 100 sweatshirts were 0.1% below the fair value. Please note that the stock promotions in Dow and other places do not necessarily turn into actual trading at the next regular stock market session.

The current stock market

Dow Jones declined by 0.3% on Monday, reaching down Boeing (BA), even as Apple (AAPL) broke out. The Nasdaq composite increased by 0.2% and S & P 500 by 0.1%. All three main indicators make up about 2% of their most recent highs, since the current rally is at the threshold of the phase of a long bull market.

Stock Zogenix Stock, GW Pharma Gains

The FDA refused to inspect Fintepla for treatment of a rare form of epilepsy later in the morning after Monday. Shares Zogenix decreased by 31.5% at the end of trading. Zogenix stock tried to explode past the 55.10 cup-by-handle purchase item on March 29 and April 1, but never closed above the entry.

Meanwhile, GW Pharma stock rose 3.5% late. Stocks are working on a point of purchase 182.33 from a short flat base after leaving a wild, very deep cup with a handle after earning money at the end of February.

GW Pharma sells Epidiolex, a cannabinoid drug, for the treatment of Dravet and other types of childhood epilepsy. The FDA approved it in June of June

FaseBio Stock Jumps

The FDA has announced the PB2452 PhaseBio Pharmaceuticals breakthrough therapy, which provides a better way to be approved. PhaseBio is an overturner agent for anti-coagulation of the AstraZeneca [AZ45] Brilinta. Stock PhaseBio increased by 34% late. Shares rose 17% to 12.57 on Monday at the stock market, striking at a new height. The shares of PhaseBio came to the public on 5 shares in October, dropped to 2.55 in November, but were tear-free from March 12th.

Bio-council at the point of purchase

FDA OK t for blood typing and screening for small and medium-sized laboratories. Bio-Rad shares were not traded late on Monday. Shares rose by 0.4% to 309.84. Bio-rad works over a point of purchase of 324.04 cups with a handle.

How to play the biotechnology sector

Individual biotechnological actions are subject to sudden spikes of news. One way to minimize the risk associated with stocks is to ETF. Among the best ETFs for ETF Biotechnology (IBB), iShares Nasdaq is nearby.

Please follow Edom Carson on Twitter in @IBD_ECarson to update the stock market and more.

] YOU ALSO LIKE:

Great picture: Indices repeat this bullish theme

Neil Portfolio Manager: The main bull market is far from excess

19659009] How to explore growth stocks: why this IBD tool makes it easy to find top stocks

Find attractive stocks of growth with a stock of IBD per day


Source link